Emergex
Closed: 29 July 2017
What we did for the company
- Conduct legal, financial and commercial due diligence for the purpose of drafting a vendor due diligence report
- Raise finance
- A £5 million equity offering for Emergex Vaccines Holding Limited in return for 50% of the equity. £5 million pre-money value
Company details
- Emergex pioneered the field of nanotechnology for biological use and developed that technology over a 15 year period after founding a successful AIM/NASDAQ listed nanotechnology company.
- EmergexVaccines Limited is focused on the development of T-Cell vaccines for infectious viral and bacterial diseases that include Ebola Virus, Dengue Virus, Marburg Virus, Influenza virus, meningitis X, bacterial pneumonia, and other emerging zoonotic agents.
T-Cell epitopes presented by SARS-Cov-2 infected cells identified
Emergex Vaccines and George Mason University identify T-Cell epitopes presented by SARS-Cov-2 infected cells
Emergex signs a multi- million dollar deal with Vickers VC.
Emergex signs a multi- million dollar deal with Vickers VC managed by Dr. Finian Tan, early stage Baidu investor– often refereed to as China's Google.